How Mums Are Getting GLP-1s Delivered Without the GP Waitlist

This article is for informational purposes only and does not constitute medical advice. Always speak with a qualified healthcare professional before starting any new medication.

If you have spent any time on a parenting forum lately, or had a long overdue catch-up with a friend who has somehow dropped two dress sizes since last summer, there is a very good chance you have heard the letters GLP-1 come up. Maybe it was mentioned quietly over coffee. 

*This is a collaborative post

Maybe someone was vague about how exactly they got hold of their medication. Maybe you nodded along whilst secretly wondering how on earth they managed to bypass the queue.

Because the queue is real. The NHS waiting list for specialist weight management services, where Wegovy (semaglutide) is currently available, stretches anywhere from twelve to twenty-four months depending on your area. That is not a rumour. Many NHS services have implemented waiting lists of this length and are restricting new initiations altogether due to the sheer volume of referrals. NICE recommended semaglutide for weight management back in 2023, but recommending something and actually making it accessible are two very different things, as anyone who has ever tried to see a physiotherapist on the NHS will already know.

So what are people actually doing? And more to the point, is it safe, and is it legal? This is a proper look at what is really going on.

What a GLP-1 Actually Does Inside Your Body

Before getting into the logistics, it helps to understand what these medications are doing. GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases naturally after you eat. It signals to your brain that you are full, slows the rate at which your stomach empties, and helps regulate blood sugar. Semaglutide mimics this hormone, essentially amplifying a process your body already runs.

The reason these drugs have caused such a stir is the clinical data behind them. The STEP 1 trial, published in the New England Journal of Medicine in 2021, found that once-weekly semaglutide at 2.4mg was associated with a mean body weight reduction of 14.9% over 68 weeks, with 86% of participants achieving at least 5% weight loss. Those are not modest numbers. For context, most older weight-loss medications were considered successful if they produced 5% weight loss. Semaglutide essentially tripled the benchmark.

What tends to get less attention is how the drug works for women specifically who are managing weight after having children. Hormonal changes through pregnancy, breastfeeding, and the general chaos of keeping small people alive while trying to sleep, can all affect how hunger signals work. GLP-1 medications do not directly target any of this, but by quieting the constant background noise of appetite, many women report that they are able to make food choices that align with how they actually want to eat rather than how exhaustion and stress have been dictating things for years.

The side effects worth knowing about

The most common side effects are gastrointestinal: nausea, occasional vomiting, and loose stools, particularly in the first few weeks as the dose increases. These are generally described as manageable and temporary. More serious effects such as pancreatitis are rare and should be discussed with a prescriber, particularly if you have a personal or family history of the condition. The MHRA’s Yellow Card scheme continues to monitor reports in the UK, and the agency has issued updated guidance for prescribers as the drugs have become more widely used.

Where People Are Actually Getting It

This is the part that raises eyebrows, and understandably so. Because when the NHS queue is two years long and private clinics in the UK are charging upwards of £200 a month for brand-name Wegovy, some mums have been looking further afield and specifically at US-based telehealth providers that work with compounding pharmacies.

Compounding pharmacies produce versions of medications to individual prescriptions. In the United States, these operate under either Section 503A (patient-specific prescriptions through state-licensed pharmacies) or Section 503B (FDA-registered outsourcing facilities). During the global semaglutide shortage between 2022 and 2025, compounding was explicitly permitted as a legal route for patients who could not access the branded drugs. The landscape has tightened since the FDA officially resolved the shortage in February 2025, but 503A pharmacies can still produce semaglutide for individual patients with a valid prescription and documented clinical need.

Several US telehealth providers have built their entire model around this, connecting patients with licensed physicians who assess their suitability, write prescriptions, and have medication dispatched directly to their door from accredited compounding pharmacies. Prices for this route typically start around $149 per month on longer plans, compared to $900 to $1,300 per month for brand-name Wegovy in the US without insurance. For those researching their options, this breakdown of the cheapest, safest compounding pharmacy providers for semaglutide ranks vetted telehealth clinics by pricing, pharmacy transparency, licensing, and the quality of ongoing medical oversight included, which matters far more than price alone.

“The drug itself means very little without a provider who will actually monitor how you respond to it.”

What the comparison makes clear is that not all providers are equal in how much clinical support they wrap around the prescription. Some include regular check-ins, dietitian access, and dose adjustment support. Others hand over the prescription and leave the rest to you. The drug itself means very little without a provider who will actually monitor how you respond to it, so the quality of the telehealth clinic matters at least as much as the price per dose.

The verification questions worth asking before committing

If you are considering this route, there are specific things to establish before parting with any money. First, is the prescribing physician licensed and named? A reputable provider will tell you exactly who is signing your prescription. Second, which compounding pharmacy will fulfil it, and does that pharmacy have a verifiable US address, current state licensure, and no active regulatory actions against it? Third, does the service require any baseline health assessment, including questions about your cardiovascular history, thyroid, and current medications? If the sign-up process takes under five minutes and skips all of that, it is not providing real medical oversight. It is just selling a product with a prescription attached.

There is also the question of what happens if something goes wrong. A clinic that has a clear escalation pathway and medical team you can actually contact is categorically different from one that communicates only by automated message. This is worth verifying before you start, not after you have paid three months up front.

The Safety Landscape in the UK Right Now

The UK picture is complicated by the fact that the MHRA and the NHS have not established a clear, accessible framework for people who want semaglutide for weight management but do not qualify for, or cannot wait for, the NHS pathway. Private UK clinics can prescribe Wegovy legally, and GPs can refer to specialist services, but neither route is fast or cheap for most families.

What the MHRA has been explicit about is the risk of counterfeit products. The World Health Organisation issued a warning in June 2024 over fake versions of semaglutide identified in the UK, and the MHRA has since shut down an illicit manufacturing facility in the East Midlands that was producing unlicensed GLP-1 medications, seizing 2,000 pens ready for shipping. The lesson there is not that all alternatives to the NHS are dangerous, but that the source genuinely matters, and sourcing anything from an unregulated online seller, a beauty salon, or a social media link is a serious risk.

Reputable US telehealth providers that ship to patients internationally operate in a different category from these illegal operations entirely. They require a prescription, partner with licensed pharmacies, and provide documented medical supervision. The key distinction is whether a qualified prescriber is involved at every stage, not whether the packaging arrived through the post.

What honest medical supervision looks like

The providers worth trusting have a few things in common. They will ask for a health questionnaire that covers your full medical history, not just your weight. They will not approve you if you have contraindications such as a personal or family history of medullary thyroid carcinoma or certain pancreatic conditions. They will escalate the dose gradually, starting at 0.25mg and moving up in stages over weeks, not hand you the maximum dose on day one. And they will have a clear process for reporting side effects and adjusting your prescription accordingly. The House of Commons Library has published a detailed briefing on GLP-1 weight-loss medicines in England, which gives useful context on how NICE and NHS England have framed eligibility and oversight expectations, and is worth reading to understand what proper supervised prescribing is supposed to look like.

The Honest Part About Cost and Commitment

Here is where this conversation gets practical, because we are all working with real budgets and real lives. The cost of going private for weight management medication is not trivial. Brand-name Wegovy privately in the UK starts at around £200 per month for medication alone, and that does not include consultation fees. The US telehealth and compounding route starts lower, often around £120 to £180 per month at current exchange rates depending on the provider and plan length, and that typically includes the online consultation, ongoing prescriber access, and delivery.

What neither route includes is a guarantee. Semaglutide works best alongside genuine changes to how you eat, not as a replacement for them. The STEP 1 trial included a lifestyle intervention component in every participant group, meaning the weight loss figures were achieved by people who were also engaged with dietary and activity guidance, not people who simply injected once a week and waited. The providers that include nutritional coaching alongside the prescription are offering something meaningfully different from those that do not, and over six or twelve months that difference tends to show.

There is also the question of what happens when you stop. The weight tends to return without ongoing lifestyle changes in place, which is why the clinical guidance consistently frames these drugs as part of a longer programme rather than a finite course.

What the Queue Actually Means for You

If you are sitting on an NHS referral waiting list right now, or wondering whether to even start the process, the picture is this: the NHS pathway is real, it is subsidised, and it comes with the full support structure of a specialist weight management service. It is also, for most people in most areas, not quick. NICE has estimated that 3.4 million people in England would be eligible for tirzepatide treatment under the current guidance, and the rollout to primary care is expected to take up to twelve years to reach all eligible patients. That is the scale of the gap.

Private UK clinics are a legitimate alternative, with faster access and the full Wegovy pen, but at a price point that puts them out of reach for a lot of families with small children and everything else that comes with that season of life. The US telehealth and compounding pharmacy route sits in the middle ground: more accessible in cost, requires careful vetting of the provider, and involves a product that is regulated differently from a UK-licensed medicine.

None of these routes is right for everyone, and none of them replaces a conversation with a doctor who knows your full medical history. But understanding what your actual options are, rather than just being told the NHS queue is the only legitimate path, is a reasonable place to start. The mums who have been quietly getting on with it already knew that. Now you do too.

This article references publicly available clinical and government sources. It does not constitute medical advice. Please consult a qualified healthcare professional before starting any medication programme.